Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

GT Bio's CEO Michael Breen said he's seen "encouraging trends" in ongoing AML Phase I trials that could validate the platform's efficacy as the company moves into solid tumors. The firm's leadership ...

Long-term data on four patients' who had received avigbagene parvec gave the firm confidence to advance a late-stage single-arm trial that can support regulatory approval.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...

"All healthcare providers should be aware of the risks of DPD deficiency," inform patients of toxicity risks, and test patients unless treatment is immediately needed, the agency said.

This year, the firm will focus on commercializing and further developing the ovarian cancer drug and discuss the registrational path with the FDA for a KRAS G12D inhibitor.